Efficacy and Tolerability of Enstilar® in Daily Practice
This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice
with regards to effectiveness and convenience of application to psoriasis plaques on body and
extremities. In addition the profiles of patients prescribed Enstilar® will be described, and
preceeding, concomitant and follow-up management will be mapped. The study will be conducted
in about 100 dermatology clinics all over Germany,
Multinational real-life study of current psoriasis treatment strategies, topical treatment
patterns and treatment outcomes of these treatments, including the newly introduced
calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar®
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.